Study on the Effects and Mechanisms of Fecal Microbiota Transplantation Based on the Gut Microbiota-Metabolite Axis in Delaying Liver Fibrosis and Inhibiting Hepatocyte Apoptosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500111201

Enrollment

Unknown

Registered

2025-10-28

Start date

2025-11-01

Completion date

Unknown

Last updated

2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of Liver Fibrosis

Interventions

Cirrhosis Group (Fecal Microbiota Transplantation):None

Healthy control group:None

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Patients with liver cirrhosis: Aged 18–65 years, meeting diagnostic criteria for liver cirrhosis, and voluntarily participating. 2. Healthy individuals: aged 18-65 years with normal liver function, no chronic liver disease, immune disorders, or recent history of antibiotic use.

Exclusion criteria

Exclusion criteria: 1. Concurrent liver cancer or other malignant tumors; 2. Recent administration of probiotics, antibiotics, or fecal microbiota transplantation (FMT); 3. Pregnant or lactating women; 4. Inability to provide informed consent.

Design outcomes

Primary

Measure	Time frame
Liver fibrosis;	—

Countries

China

Contacts

Public ContactRongrong Chen

Fuzhou University Affiliated Provincial Hospital

18650303056@163.com+86 186 5030 3056

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026